Nanoparticles that both sense and stimulate brain chemicals

Building a two-way communication system: Bio-orthogonal superhydrophobic nanoparticles for controlled stimulation and real-time sensing of neurotransmitters

NIH-funded research University of Southern California · NIH-11014650

This project develops tiny nanoparticles that can detect and release brain chemicals like acetylcholine to help researchers better understand and treat Alzheimer’s disease.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of Southern California NIH-funded
Lab location1 site (Los Angeles, UNITED STATES)
Project IDNIH-11014650 on NIH RePORTER

What this research studies

Researchers are designing fluorous (fluorine-rich) nanoparticles that can do two things at once: read levels of ions and neurotransmitters such as acetylcholine, and release molecules when activated by light. These particles will be tested in lab-grown neurons and animal models and developed toward in vivo imaging so scientists can watch chemical signaling in real time. The approach aims to be chemically 'invisible' until it meets its target, reducing background noise and improving specificity. Over time this tool could reveal how chemical signaling goes wrong in Alzheimer’s and point to new ways to intervene.

Who could benefit from this research

Good fit: People with Alzheimer’s disease or mild cognitive impairment could be candidates for future clinical imaging studies once the nanoparticles are shown to be safe for humans.

Not a fit: Patients who cannot undergo the required imaging procedures, have incompatible implants, or have serious medical conditions that prevent participation may not benefit from this work.

Why it matters

Potential benefit: If successful, this technology could reveal early chemical changes in the brain and help guide better diagnostics and treatments for Alzheimer’s disease.

How similar studies have performed: Related chemical sensors and nanoparticle probes exist in laboratory research, but the combined bio-orthogonal, fluorous nanoparticles that both sense and release neurotransmitters in vivo are a novel approach.

Where this research is happening

Los Angeles, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndromeAlzheimer's Disease
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.